Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 1/2 8Phase 3 3Phase 1 3Phase 2/3 2Phase EARLY_PHASE1 1

Status

Recruiting 5Completed 4Active not recruiting 3Terminated 1Suspended 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 2Skin Neoplasms 1Neoplasm Metastasis 1Cutaneous Squamous Cell Carcinoma 1

Interventions

Carboplatin 106Cisplatin 97Paclitaxel 78pembrolizumab 69Gemcitabine 59Pemetrexed 49Cyclophosphamide 46Docetaxel 45Dexamethasone 45durvalumab 44Capecitabine 44Radiotherapy 40Nivolumab 37Lenalidomide 37Specimen Handling 36Doxorubicin 36Rituximab 34Oxaliplatin 34Bevacizumab 33Magnetic Resonance Spectroscopy 32Fluorouracil 32atezolizumab 29Etoposide 29Vincristine 26Radiation 26Leucovorin 26Letrozole 24Bortezomib 24Fulvestrant 23Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × cemiplimab × Clear all
NCT05352672 2026-04-22

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
1,546 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT03969004 2026-03-27

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
415 enrolled 1 FDA
Dermatologic

Cutaneous Squamous Cell Carcinoma

NCT05608291 2025-05-13

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
1,564 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡